We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Var3.6
Vardenafil (Levitra) Research
Mostly mechanism / observational
26 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Vardenafil (Levitra) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2001–2026 with a typical study size of 765 participants.
Based on 26 studies · 2 meta-analyses · 13 RCTs · 2,795 total participants
Confidence
High confidence
By outcome
Erectile functionRobust RCT and meta-analytic evidence for dose-dependent, clinically meaningful improvement in erectile function versus placebo, including in men with diabetes and after prostatectomy · ~30-60 minutes (on-demand)
Mostly mechanism / observational14 studies
Cardiovascular & vascular
Mostly mechanism / observational9 studies
Safety profile
Mostly mechanism / observational9 studies
Active research area
15 studies in the last 5 years · Latest meta-analysis: 2025
200120132026
1RCT2016
Santi D, Granata AR, Guidi A, Pignatti E, Trenti T, Roli L · Eur J Endocrinol (2016)
In plain English: However, the overall certainty of evidence is low, and further validation in well-designed, multiethnic studies is required before clinical translation.
Ferezin LP, Kayzuka C, Paiva de Alcântara E Silva M, Tavares Peixeiro CN, Rondon-Pereira VC, Tanus-Santos JE, Lacchini R. · Frontiers in pharmacology (2026)
However, methodological limitations were pervasive: 77.8% of studies had moderate risk of bias, and 80.6% showed low certainty of evidence.
Only one study reached moderate certainty.
Discussion/conclusion Current evidence suggests that genetic polymorphisms related to nitric oxide signaling, vascular regulation, and PDE5 inhibitor pharmacodynamics are associated with variability in erectile dysfunction risk and treatment response.
In plain English: Cross-sectional findings reveal substantial literacy-stratified disparities in treatment utilization and adherence, warranting prospective trials of routine health literacy assessment and tiered intervention strategies to reduce inequities and improve sexual health outcomes.
Wei L, Wu Y, Wei F, Yi Y. · Frontiers in public health (2026)
Structural equation modeling indicated that health literacy was statistically associated with an indirect pathway consistent with partial mediation of the knowledge and practice association (proportion mediated 0.31; 95% CI: 0.18-0.49; p < 0.001).
Treatment barriers decreased systematically: side effect concerns (44.1% vs. 28.1%, OR 0.51, p < 0.001), embarrassment (35.1% vs. 20.8%, OR 0.49, p < 0.001), and cost concerns (49.1% vs. 32.3%, OR 0.50, p < 0.001).
Information-seeking behaviors increased dramatically with higher literacy: active health information seeking (35.1% vs. 66.2%, OR 3.64, p < 0.001) and digital resource use (27.0% vs. 61.2%, OR 4.27, p < 0.001).
In plain English: Conclusion In summary, this review helps doctors and researchers by providing clear information about PDE5 inhibitor drugs for ED and pointing out areas where more research can improve treatment and quality of life for men with this condition.
Rajasekhar AT, Un-Nabi SS, Kaliyamoorthy S, Anusha D, S N. · The Journal of pharmacy and pharmacology (2026)
Key findings PDE5 inhibitors significantly improve erectile function compared with placebo across diverse patient populations.
Adverse events are generally mild, transient, and dose-related, with a favourable benefit-risk profile when prescribed in accordance with contraindications and cardiovascular risk assessment.
Alternative therapies are effective in PDE5 inhibitor non-responders.
In plain English: The aim of this narrative revision of the current literature is to demonstrate that (i) the orodispersible film of sildenafil is safe from a CV perspective; (ii) it is a discreet formulation that respects the need for privacy; and (iii) it is virtually the unique PDE5i formulation too expensive to produce outside the correct channels, making it impossible to be counterfeit.
Sansone A, Guida E, Dolci S, Frangione V, Asso A, Bellia G, Jannini EA. · Basic and clinical andrology (2025)
However, the use of PDE5is has faced several challenges.
Many patients and some healthcare providers (HCPs) often share the misconception that using these drugs can increase the risk of CVD.
Some patients might desire to fulfill the unmet need for privacy linked to the stigma of being treated for ED or might be enticed by the idea of buying drugs online, either because of shame or cheaper prices, without knowing the risks associated with counterfeit drugs.
In plain English: Conclusion Simenafil is an effective and well-tolerated therapy for patients with ED.
Yang Y, Zhang X, Jiang T, Zhao L, Li F, Yao W, Deng J, Zhang X, Yang J, Ji Z, Tong Z, Chen Y, Wang Z, Juan J, Duan H, Jiang H. · The journal of sexual medicine (2025)
Results A total of 765 patients were randomized and 92.3% completed the study.
The mean age of subjects was 41.3 years and 81.6% had moderate to severe ED (mean overall International Index of Erectile Function-Erectile Function (IIEF-EF) domain score 13.4).
Adverse drug reactions (ADRs) occurred in 36.2% of patients who received simenafil (32.6% in simenafil 5 mg group, the clinically recommended dose) and in 30.9% of those who received placebo.
In plain English: SIGNIFICANCE STATEMENT: This review discusses the molecular changes that reduce NO-cGMP bioavailability in the penis in SCD and highlights pharmacological targets and therapeutic strategies for the treatment of priapism, including PDE5 inhibitors, hormonal modulators, NO donors, hydroxyurea, soluble guanylate cyclase stimulators, haptoglobin, hemopexin, and antioxidants.
Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. · The Journal of pharmacology and experimental therapeutics (2024)
We also further discuss the impact of intravascular hemolysis on therapeutic approaches, present current pharmacological strategies targeting the NO-cGMP-PDE5 pathway in the penis, and identify potential pharmacological targets for future priapism therapies.
In men with SCD and priapism, PDE5 inhibitor therapy and testosterone replacement have shown promising results.
Recent preclinical research reported the beneficial effect of treatment with haptoglobin and NO donors.
In plain English: Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.
Lan TY, Chiang CH, Chen JW, Chang TT. · Journal of the Chinese Medical Association : JCMA (2025)
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia.
Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation.
Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.
In plain English: We hope that this summary will aid in better understanding of PDE5 inhibitors and provide insights for developing novel therapies targeting PDE5.
Zong T, Huang X, Zhou W, Hu Z, Jin L, Zhan P, Zhao Y, Sun J, Li G. · European journal of medicinal chemistry (2025)
Therefore, the development of novel, isozyme-selective PDE5 inhibitors is highly warranted.
In this review, we systematically summarize the research progress of PDE5 inhibitors over the past 20 years, focusing on the meticulously combing and categorizing the structures of PDE5 inhibitors and natural products exhibiting PDE5 inhibitory activities, along with their therapeutic potentials.
We hope that this summary will aid in better understanding of PDE5 inhibitors and provide insights for developing novel therapies targeting PDE5.
In plain English: Further focused studies are warranted to confirm these findings and define optimal doses and duration of therapy.
Tienforti D, Felzani G, Di Pasquale AB, Barbonetti A. · Andrology (2025)
Overall, at the pairwise meta-analysis, PDE5i were four times more effective than placebo in improving erectile function (risk ratio: 4.13, 95% CI: 2.76, 6.19).
The comparative analysis from NMA revealed that tadalafil was associated with the highest SUCRA value (81%), followed by vardenafil (68%) and sildenafil (49%).
Discussion and conclusion Within the grading of comparison network, tadalafil appeared to be the best PDE5i in the treatment of SCI-related ED.
In plain English: However, there are limitations to the evidence that should be considered.
· Unknown Journal (2025)
What did we find? • We identified 3 relevant clinical studies.
What does this mean? • Initial combination therapy with 2 oral medications, an ERA and a PDE5 inhibitor, may provide better treatment outcomes in patients with PAH compared to monotherapy.
However, there are limitations to the evidence that should be considered.
18RCT2025
In plain English: In conclusion, TPN171 can be cautiously used in patients with mild to severe renal impairment.
Fu P, Song Y, Hu C, Yong X, Yu Y, Chen Y, Wang Y, Zhu X, Wang Z, Wang Y, Juan J, Chen Y, Miao J. · Clinical pharmacology in drug development (2025)
Elimination half-life was prolonged and clearance was decreased in severe renal impairment group.
The adverse reaction rate showed no significant difference.
All adverse events were mild intensity, and no participant was discontinued in this study.
In plain English: Considering the increase in TPN171 plasma exposure, the highest dose of 5 mg TPN171 is recommended in patients with ED having mild-to-moderate HI.
Zhou J, Zhang H, Ding Y, Wang Z, Wang Y, Juan J, Jiang Z, Chen H. · Clinical pharmacology in drug development (2025)
The maximum plasma concentration (C max ), area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC 0-t ), and AUC extrapolated to infinite time (AUC 0-∞ ) were compared between the groups.
C max , AUC 0-t , and AUC 0-∞ were higher in groups A and B than in group C (geometric mean ratios 1.17-1.20, 1.46-1.53, and 1.45-1.54, respectively), while the elimination half-time was prolonged and clearance was reduced in the HI groups.
All adverse events were not serious and no participant withdrew from this study.
In plain English: New indications and applications were reviewed in depth.
Rosen RC, Miner M, Burnett AL, Blaha MJ, Ganz P, Goldstein I, Kim N, Kohler T, Lue T, McVary K, Mulhall J, Parish SJ, Sadeghi-Nejad H, Sadovsky R, Sharlip I, Kloner RA. · Sexual medicine reviews (2024)
Sixth, recommendations were made regarding over-the-counter access and potential risks of dietary supplement adulteration.
Seventh, although limited data exist in women, PDE5 inhibitors are generally safe and are being tested for use in multiple new indications.
Conclusion Studies support the overall cardiovascular safety of the PDE5 inhibitors.